Parecoxib, Valdecoxib, and Cardiovascular Risk
- 25 January 2005
- journal article
- editorial
- Published by Wolters Kluwer Health in Circulation
- Vol. 111 (3) , 249
- https://doi.org/10.1161/01.cir.0000155081.76164.17
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgeryThe Journal of Thoracic and Cardiovascular Surgery, 2003
- Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2Science, 2002
- Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2Proceedings of the National Academy of Sciences, 1999